Ainos, Inc.

Equities

AIMD

US00902F3038

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-06-24 EDT			5-day change	1st Jan Change
0.836 ^USD	+0.70%		-1.62%	-59.22%

06-14	Ainos, Inc. Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA	CI
05-15	Ainos to Start Clinical Trial of Potential Animal Drug for Oral Disease Treatment	MT

Ainos, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 13, 2024 at 04:11 pm

Ainos, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 0.020729 million compared to USD 0.049164 million a year ago. Net loss was USD 3.31 million compared to USD 2.52 million a year ago.

Basic loss per share from continuing operations was USD 0.57 compared to USD 0.63 a year ago. Diluted loss per share from continuing operations was USD 0.57 compared to USD 0.63 a year ago.

Latest news about Ainos, Inc.

Ainos, Inc. Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA	06-14	CI
Ainos to Start Clinical Trial of Potential Animal Drug for Oral Disease Treatment	05-15	MT
Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market	05-15	CI
Earnings Flash (AIMD) AINOS Reports Q1 Revenue $20,729	05-13	MT
Ainos, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Ainos, Inc. Appoints Christopher Hsin-Liang Lee as Chief Financial Officer	03-19	CI
Ainos, Inc. Announces Resignation of Meng-Lin Sung, the Chief Financial Officer	03-15	CI
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	03-11	MT
Top Premarket Decliners	03-11	MT
Ainos, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-08	CI
Top Premarket Gainers	03-08	MT
Ainos Submits Clinical Hold Complete Response to US FDA to Address Issues in Phase 2 Veldona Trial	02-05	MT
Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms	02-05	CI
Ainos, Inc. Enters into Five-Year Product Development Agreement with Taiwan Carbon Nano Technology Corporation	01-12	CI
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	01-05	MT
Ainos Regains Compliance With Nasdaq Listing Rule	01-02	MT
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell	12-26	CI
Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary	12-22	CI
Ainos Says Three Clinical Studies for Veldona Show 'Positive' Data	11-21	MT
Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA	11-21	CI
Earnings Flash (AIMD) AINOS Reports Q3 Revenue $24,489	11-09	MT
Ainos, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Ainos, Inc. Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on Veldona	11-06	CI
Ainos to Issue Preliminary $3 Million Portion of Expected $10 Million Notes Placement	23-09-25	MT
Ainos Says Candidate Treatment for HIV Oral Warts Gets Orphan Drug Designation	23-09-18	MT

Chart Ainos, Inc.

Duration

Period

More charts

Company Profile

Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AINOS, INC.	-59.22%	5.44M
VERTEX PHARMACEUTICALS INCORPORATED	+16.73%	123B
REGENERON PHARMACEUTICALS, INC.	+21.13%	115B
ARGENX SE	+18.05%	25.85B
BIONTECH SE	-17.94%	20.9B
GENMAB A/S	-16.24%	16.52B
BEIGENE, LTD.	-11.76%	16.77B
WUXI APPTEC CO., LTD.	-44.45%	15.56B
SAREPTA THERAPEUTICS, INC.	+69.92%	15.49B
NEUROCRINE BIOSCIENCES, INC.	+1.41%	13.45B

Bio Therapeutic Drugs